Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -0.05% is 100% above its 5-year average of -59.32%, near the high end of its 5-year range (-145.85%–-0.05%).
99.87% above its 12-month average of -38.03%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -0.01%.
RETURN ON ASSETS (ROA)
-0.05%
RETURN ON ASSETS (ROA) AVG TTM
-38.03%
RETURN ON ASSETS (ROA) AVG 3Y
-60.31%
RETURN ON ASSETS (ROA) AVG 5Y
-59.32%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+99.87%
CURRENT VS 3Y AVG
+99.92%
CURRENT VS 5Y AVG
+99.92%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.12%
median of 526 covered companies
CURRENT VS SECTOR MEDIAN
+99.82%
vs the sector median at left
Coya Therapeutics, Inc.
Market Cap
$114.47M
Return on Assets (ROA)
-0.05%
TTM Avg
-38.03%
3Y Avg
-60.31%
5Y Avg
-59.32%
Market Cap
$114.76M
Return on Assets (ROA)
-53.26%
TTM Avg
-24.98%
3Y Avg
-43.10%
5Y Avg
-143.56%
Market Cap
$115.66M
Return on Assets (ROA)
-85.80%
TTM Avg
-37.85%
3Y Avg
-56.27%
5Y Avg
-56.27%
Market Cap
$112.31M
Return on Assets (ROA)
-34.04%
TTM Avg
-20.59%
3Y Avg
-37.88%
5Y Avg
-37.10%
Market Cap
$116.84M
Return on Assets (ROA)
-31.75%
TTM Avg
-34.00%
3Y Avg
-32.33%
5Y Avg
-29.29%
Market Cap
$117.03M
Return on Assets (ROA)
-128.96%
TTM Avg
-127.49%
3Y Avg
-112.64%
5Y Avg
-129.28%
Market Cap
$111.89M
Return on Assets (ROA)
-134.18%
TTM Avg
-145.83%
3Y Avg
-164.39%
5Y Avg
-180.40%
Market Cap
$111.78M
Return on Assets (ROA)
-4.60%
TTM Avg
-3.66%
3Y Avg
-5.21%
5Y Avg
-1.02%
Market Cap
$110.75M
Return on Assets (ROA)
-14.14%
TTM Avg
-26.48%
3Y Avg
-30.34%
5Y Avg
-26.58%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | $114.47M | -0.05% | -38.03% | -60.31% | -59.32% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $114.76M | -53.26% | -24.98% | -43.10% | -143.56% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.66M | -85.80% | -37.85% | -56.27% | -56.27% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $112.31M | -34.04% | -20.59% | -37.88% | -37.10% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.84M | -31.75% | -34.00% | -32.33% | -29.29% |
| Genelux Corporation (GNLX)vs › | $117.03M | -128.96% | -127.49% | -112.64% | -129.28% |
| Lucid Diagnostics Inc. (LUCD)vs › | $111.89M | -134.18% | -145.83% | -164.39% | -180.40% |
| BGM Group Ltd. (BGM)vs › | $111.78M | -4.60% | -3.66% | -5.21% | -1.02% |
| Apyx Medical Corporation (APYX)vs › | $110.75M | -14.14% | -26.48% | -30.34% | -26.58% |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.52M | -72.42% | -66.03% | -45.57% | -48.77% |
ROA
-0.1%
ROE
-0.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -42.49% |
| 2024-12-31 | -33.56% |
| 2023-12-31 | -19.36% |
| 2022-12-31 | -145.85% |
| 2021-12-31 | -102.08% |
| 2020-12-31 | -12.57% |
